Headlines about Regulus Therapeutics (NASDAQ:RGLS) have trended somewhat positive recently, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Regulus Therapeutics earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.2089669298025 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news articles that may have effected Accern’s scoring:
- BRIEF-Regulus Announces First-in-Human Dosing For Phase I Study Of RGLS4326 (reuters.com)
- Regulus Announces First-in-Human Dosing for Phase I Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (finance.yahoo.com)
- Leading Healthcare stock Regulus Therapeutics Inc. (RGLS) – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Regulus Therapeutics (RGLS) Rating Lowered to Hold at Zacks Investment Research (americanbankingnews.com)
- Remarkable Runner -Regulus Therapeutics Inc. (RGLS) – Nasdaq Fortune (press release) (nasdaqfortune.com)
RGLS has been the subject of a number of research reports. Zacks Investment Research upgraded Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research report on Saturday, September 16th. Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a research report on Tuesday, November 14th. Finally, Wedbush reiterated an “outperform” rating and set a $4.00 target price on shares of Regulus Therapeutics in a research report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $2.60.
COPYRIGHT VIOLATION WARNING: This story was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.com-unik.info/2017/12/20/regulus-therapeutics-rgls-getting-somewhat-favorable-news-coverage-study-finds.html.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.